Center-Authored Papers

Filters: Author is Meshinchi, Soheil  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Young Adult
Ho PA, Zeng R, Alonzo TA, Gerbing RB, Miller KL, Pollard JA, Stirewalt DL, Heerema NA, Raimondi SC, Hirsch B et al..  2010.  Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.. Blood. 116(5):702-10. Abstract
Ho PA, Alonzo TA, Kopecky KJ, Miller KL, Kuhn J, Zeng R, Gerbing RB, Raimondi SC, Hirsch BA, Oehler VG et al..  2010.  Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 24(5):909-13. Abstract
Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, Dahl G, Lacayo NJ, Becton D, Chang M et al..  2010.  Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.. Blood. 115(12):2372-9. Abstract
Walter RB, Alonzo TA, Gerbing RB, Ho PA, Smith FO, Raimondi SC, Hirsch BA, Gamis AS, Franklin JL, Hurwitz CA et al..  2010.  High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(17):2831-8. Abstract
Bhatla D, Gerbing RB, Alonzo TA, Conner H, Ross JA, Meshinchi S, Zhai X, Zamzow T, Mehta PA, Geiger H et al..  2009.  Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia.. British journal of haematology. 144(3):388-94. Abstract
Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman PW, Taub J, Pounds S, Razzouk BI, Lacayo NJ, Cao X et al..  2010.  Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.. The lancet oncology. 11(6):543-52. Abstract
Ho PA, Kopecky KJ, Alonzo TA, Gerbing RB, Miller KL, Kuhn J, Zeng R, Ries RE, Raimondi SC, Hirsch BA et al..  2011.  Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric/adult AML: a report from the Children's Oncology Group and SWOG.. Blood. 118(17):4561-6. Abstract
Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley ITW, Meshinchi S, Bhatla D, Radloff G, Davies SM.  2010.  MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group.. Pediatric blood & cancer. 55(2):248-53. Abstract
Ho PA, Kutny MA, Alonzo TA, Gerbing RB, Joaquin J, Raimondi SC, Gamis AS, Meshinchi S.  2011.  Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.. Pediatric blood & cancer. 57(2):204-9. Abstract
Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C, Heerema NA, Hirsch B, Raimondi SC, Lange B et al..  2009.  Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.. Blood. 113(26):6558-66. Abstract
United States
Ho PA, Kutny MA, Alonzo TA, Gerbing RB, Joaquin J, Raimondi SC, Gamis AS, Meshinchi S.  2011.  Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.. Pediatric blood & cancer. 57(2):204-9. Abstract
Tumor Markers, Biological
Radhi M, Meshinchi S, Gamis A.  2010.  Prognostic factors in pediatric acute myeloid leukemia.. Current hematologic malignancy reports. 5(4):200-6. Abstract
Stirewalt DL, Meshinchi S, Kopecky KJ, Fan W, Pogosova-Agadjanyan EL, Engel JH, Cronk MR, Dorcy KS, McQuary AR, Hockenbery DM et al..  2008.  Identification of genes with abnormal expression changes in acute myeloid leukemia.. Genes, chromosomes & cancer. 47(1):8-20. Abstract
Ho PA, Alonzo TA, Kopecky KJ, Miller KL, Kuhn J, Zeng R, Gerbing RB, Raimondi SC, Hirsch BA, Oehler VG et al..  2010.  Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 24(5):909-13. Abstract
Tumor Cells, Cultured
Pulikkan JA, Peramangalam PS, Dengler V, Ho PA, Preudhomme C, Meshinchi S, Christopeit M, Nibourel O, Müller-Tidow C, Bohlander SK et al..  2010.  C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations.. Blood. 116(25):5638-49. Abstract
Stirewalt DL, Meshinchi S, Kopecky KJ, Fan W, Pogosova-Agadjanyan EL, Engel JH, Cronk MR, Dorcy KS, McQuary AR, Hockenbery DM et al..  2008.  Identification of genes with abnormal expression changes in acute myeloid leukemia.. Genes, chromosomes & cancer. 47(1):8-20. Abstract
Treatment Outcome
Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley ITW, Meshinchi S, Bhatla D, Radloff G, Davies SM.  2010.  MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group.. Pediatric blood & cancer. 55(2):248-53. Abstract
Ho PA, Zeng R, Alonzo TA, Gerbing RB, Miller KL, Pollard JA, Stirewalt DL, Heerema NA, Raimondi SC, Hirsch B et al..  2010.  Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.. Blood. 116(5):702-10. Abstract
Bhatla D, Gerbing RB, Alonzo TA, Mehta PA, Deal K, Elliott J, Meshinchi S, Geiger H, Perentesis JP, Lange BJ et al..  2008.  DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 22(2):265-72. Abstract
Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, Dahl G, Lacayo NJ, Becton D, Chang M et al..  2010.  Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.. Blood. 115(12):2372-9. Abstract
Walter RB, Alonzo TA, Gerbing RB, Ho PA, Smith FO, Raimondi SC, Hirsch BA, Gamis AS, Franklin JL, Hurwitz CA et al..  2010.  High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(17):2831-8. Abstract
Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C, Heerema NA, Hirsch B, Raimondi SC, Lange B et al..  2009.  Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.. Blood. 113(26):6558-66. Abstract
Translocation, Genetic
Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, Dahl G, Lacayo NJ, Becton D, Chang M et al..  2010.  Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.. Blood. 115(12):2372-9. Abstract
Transcription, Genetic
Pui C-H, Carroll WL, Meshinchi S, Arceci RJ.  2011.  Biology, risk stratification, and therapy of pediatric acute leukemias: an update.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(5):551-65. Abstract
Tandem Repeat Sequences
Meshinchi S, Stirewalt DL, Alonzo TA, Boggon TJ, Gerbing RB, Rocnik JL, Lange BJ, Gilliland GD, Radich JP.  2008.  Structural and numerical variation of FLT3/ITD in pediatric AML.. Blood. 111(10):4930-3. Abstract